Resource · Updated 27 August 2026
Peptide Research Comparisons
Side-by-side comparisons of research compounds based on structure, mechanism and published literature — not on human-use or treatment recommendations.
CJC-1295 With DAC vs Without DAC
CJC-1295 is a synthetic growth-hormone-releasing-hormone (GHRH) analogue. The defining difference is the DAC (Drug Affinity Complex) moiety, which binds serum albumin and markedly changes the molecule's time-course in a research setting.
| Aspect | CJC-1295 with DAC | CJC-1295 without DAC |
|---|---|---|
| Structural difference | Carries a DAC (Drug Affinity Complex) moiety that binds serum albumin. | Lacks the DAC moiety; also known as modified GRF (1-29). |
| Research characteristics | Albumin binding produces an extended presence in experimental models. | A shorter time-course; closer in profile to the native GHRH fragment. |
| Half-life discussed in literature | Reported in literature as prolonged, attributed to albumin binding. | Reported in literature as notably shorter than the DAC form. |
| Mechanistic differences | Acts through the GHRH receptor with sustained exposure. | Acts through the GHRH receptor with more transient exposure. |
| Related research | Long-acting GHRH-analogue studies. | GHRH-analogue and secretagogue co-administration studies. |
Semaglutide vs Tirzepatide vs Retatrutide Research
Three metabolic research compounds distinguished primarily by the number and kind of receptors they engage — a single incretin receptor, two, or three.
| Aspect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Target receptors | GLP-1 receptor | GIP and GLP-1 receptors | GLP-1, GIP and glucagon receptors |
| Compound type | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist | Triple GLP-1/GIP/glucagon agonist |
| Mechanism investigated | Incretin-mediated glucose and metabolic signalling. | Combined GIP and GLP-1 signalling. | GLP-1, GIP and glucagon receptor co-activation. |
| Development / research history | The earliest of the three to enter wide study. | Studied as a next-step beyond single-receptor agonism. | The most recently introduced; still accumulating literature. |
| Published study landscape | Extensive clinical and preclinical literature. | Substantial and growing literature. | Emerging literature, comparatively smaller volume. |
BPC-157 vs TB-500 Research
Two frequently co-studied repair-related research peptides with distinct identities and proposed pathways, often combined in experimental models.
| Aspect | BPC-157 | TB-500 |
|---|---|---|
| Compound type | A 15-amino-acid synthetic peptide (pentadecapeptide). | A synthetic fragment of thymosin beta-4. |
| Research background | Derived from a gastric-juice protective protein. | Derived from a thymic peptide involved in actin regulation. |
| Proposed pathways | Cytoprotection and repair-associated signalling. | Actin dynamics and cell migration. |
| Areas investigated | Tissue repair and cytoprotection models. | Cell migration and angiogenesis models. |
| Available literature | Predominantly preclinical studies. | Preclinical studies, including actin-binding characterisation. |
More research references
Browse the full research library or the compound directory.